Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group.

BACKGROUND: SARS-CoV-2 infection is clinically very heterogeneous, varying from asymptomatic to severe clinical conditions with a fatal outcome. Some studies suggests that the ABO blood group could be a biological marker of susceptibility for the development of the disease. MATERIAL AND METHODS: We collected data from patients admitted with COVID-19 infection who had ABO blood group recorded, and analyzed the incidence by groups, compared with the global population in Navarre, as well as their main complications and evolution. RESULTS: Group O was proportionally less represented in the hospitalized patients with respect to the global population, although the difference was not statistically significant. Group B had significantly higher rates of thrombotic complications and required more admissions in intensive care units. CONCLUSION: The study suggests a lower susceptibility to infection in group O and a higher risk of complications in group B. Studies with a larger sample size are required in order to obtain significant results.

INTRODUCCIÓN: La infección por SARS-CoV-2, presenta gran heterogeneidad clínica, desde asintomática hasta cuadros clínicos graves con un desenlace fatal. Algunos autores refieren el grupo sanguíneo ABO como posible marcador biológico de susceptibilidad para la enfermedad. PACIENTES Y MÉTODOS: Se han recogido los pacientes ingresados con infección por COVID-19 y se ha analizado la incidencia por grupos en relación con la base poblacional de la Comunidad Foral de Navarra, así como sus principales complicaciones y evolución. RESULTADOS: Los pacientes de grupo O ingresados con infección por COVID-19 son proporcionalmente menos respecto a la base poblacional sin ser la diferencia estadísticamente significativa. Los grupos AB y B son un 38% más en el grupo de infectados que en la población. El grupo B ha presentado significación estadística en cuanto al número de complicaciones trombóticas junto con mayor tasa de ingreso en unidades de cuidados intensivos. CONCLUSIÓN: El estudio sugiere menor susceptibilidad a la infección de los pacientes de grupos O y mayor riesgo de complicaciones en el grupo B. Hacen falta estudios con mayor tamaño muestral para poder obtener resultados significativos.

Infección y trombosis asociada a la COVID-19: posible papel del grupo sanguíneo ABO / Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group

INTRODUCCIÓN: La infección por SARS-CoV-2 presenta gran heterogeneidad clínica, desde asintomática hasta cuadros clínicos graves con un desenlace fatal. Algunos autores refieren el grupo sanguíneo ABO como posible marcador biológico de susceptibilidad para la enfermedad. PACIENTES Y MÉTODOS: Se ha recogido a los pacientes ingresados con infección por COVID-19 y se ha analizado la incidencia por grupos en relación con la base poblacional de la Comunidad Foral de Navarra, así como sus principales complicaciones y evolución. RESULTADOS: Los pacientes de grupo O ingresados con infección por COVID-19 son proporcionalmente menos respecto a la base poblacional, sin ser la diferencia estadísticamente significativa. Los grupos AB y B son un 38% más en el grupo de infectados que en la población. El grupo B ha presentado significación estadística en cuanto al número de complicaciones trombóticas junto con mayor tasa de ingreso en unidades de Cuidados Intensivos. CONCLUSIÓN: El estudio sugiere menor susceptibilidad a la infección de los pacientes de grupos O y mayor riesgo de complicaciones en el grupo B. Hacen falta estudios con mayor tamaño muestral para poder obtener resultados significativos

BACKGROUND: SARS-CoV-2 infection is clinically very heterogeneous, varying from asymptomatic to severe clinical conditions with a fatal outcome. Some studies suggests that the ABO blood group could be a biological marker of susceptibility for the development of the disease. PATIENTS AND METHODS: We collected data from patients admitted with COVID-19 infection who had ABO blood group recorded, and analyzed the incidence by groups, compared with the global population in Navarre, as well as their main complications and evolution. RESULTS: Group O was proportionally less represented in the hospitalized patients with respect to the global population, although the difference was not statistically significant. Group B had significantly higher rates of thrombotic complications and required more admissions in intensive care units. CONCLUSION: The study suggests a lower susceptibility to infection in group O and a higher risk of complications in group B. Studies with a larger sample size are required in order to obtain significant results

[Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group]. / Infección y trombosis asociada a la COVID-19: posible papel del grupo sanguíneo ABO.

BACKGROUND: SARS-CoV-2 infection is clinically very heterogeneous, varying from asymptomatic to severe clinical conditions with a fatal outcome. Some studies suggests that the ABO blood group could be a biological marker of susceptibility for the development of the disease. PATIENTS AND METHODS: We collected data from patients admitted with COVID-19 infection who had ABO blood group recorded, and analyzed the incidence by groups, compared with the global population in Navarre, as well as their main complications and evolution. RESULTS: Group O was proportionally less represented in the hospitalized patients with respect to the global population, although the difference was not statistically significant. Group B had significantly higher rates of thrombotic complications and required more admissions in intensive care units. CONCLUSION: The study suggests a lower susceptibility to infection in group O and a higher risk of complications in group B. Studies with a larger sample size are required in order to obtain significant results.

Source identification of autochthonous-introduced Plasmodium vivax Malaria, Spain.

In 2014, an autochthonous case of introduced malaria caused by Plasmodium vivax was identified in Spain. The strain that infected this patient was identical to that of a prior imported case from Pakistan. This is the first case where the source of infection could be identified since elimination in Spain.